Lenalidomide for the treatment of relapsed and refractory multiple myeloma

Lenalidomide is an amino-substituted derivative of thalidomide with direct antiproliferative and cytotoxic effects on the myeloma tumor cell, as well as antiangiogenic activity and immunomodulatory effects. Together with the introduction of bortezomib and thalidomide, lenalidomide has significantly...

Full description

Saved in:

Bibliographic Details
Main Authors:	van de Donk, Niels WCJ, Görgün, Güllü, Groen, Richard WJ, Jakubikova, Jana, Mitsiades, Constantine S, Hideshima, Teru, Laubach, Jacob, Nijhof, Inger S, Raymakers, Reinier A, Lokhorst, Henk M, Richardson, Paul G, Anderson, Kenneth C
Format:	Artigo
Language:	Inglês
Published:	Dove Medical Press 2012
Subjects:	Review
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3430086/ https://ncbi.nlm.nih.gov/pubmed/22956884 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S27087
Tags:	Add Tag No Tags, Be the first to tag this record!

Lenalidomide for the treatment of relapsed and refractory multiple myeloma

Similar Items